Melanie Senior
AstraZeneca PLC has proved its skills in the marketplace, with its top five drugs accounting for more than 50% of...
David Brennan has sharpened AstraZeneca's therapeutic area focus and embraced external R&D. The next two years will determine whether the productivity drive is working--or if more radical change is needed.
Melanie Senior
AstraZeneca PLC has proved its skills in the marketplace, with its top five drugs accounting for more than 50% of...
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.